Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor

Samantha Podurgiel, Lyndsey E. Collins-Praino, Samantha Yohn, Patrick Arthur Randall, Arthur Roach, Christophe Lobianco, John D. Salamone

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. The present experiments were performed to evaluate the ability of safinamide to attenuate parkinsonian motor impairments using the tremulous jaw movement model, an animal model of parkinsonian tremor. In rats, tremulous jaw movements can be induced with dopamine (DA) antagonists, DA depletion, and cholinomimetics, and can be reversed by various antiparkinsonian drugs, including L-DOPA, DA agonists, anticholinergics and adenosine A2A antagonists. In these present experiments, tremulous jaw movements were induced with the anticholinesterase galantamine (3.0 mg/kg IP), the muscarinic agonist pilocarpine (0.5 mg/kg IP), and the dopamine D2 antagonist pimozide (1.0 mg/kg IP). Safinamide significantly reduced the number of tremulous jaw movements induced by galantamine, pilocarpine, and pimozide, with consistent effects across all three drugs at a dose range of 5.0-10.0 mg/kg. The results of this study support the use of safinamide as a treatment for parkinsonian tremor.

Original languageEnglish (US)
Pages (from-to)105-111
Number of pages7
JournalPharmacology Biochemistry and Behavior
Volume105
DOIs
StatePublished - Apr 1 2013

Fingerprint

Tremor
Animals
Jaw
Animal Models
Galantamine
Pimozide
Pilocarpine
Pharmaceutical Preparations
Dopamine Agonists
Antiparkinson Agents
Muscarinic Agonists
Phase III Clinical Trials
Monoamine Oxidase Inhibitors
Dopamine Antagonists
Cholinesterase Inhibitors
Monoamine Oxidase
Cholinergic Antagonists
Levodopa
Adenosine
Cholinergic Agents

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

Podurgiel, Samantha ; Collins-Praino, Lyndsey E. ; Yohn, Samantha ; Randall, Patrick Arthur ; Roach, Arthur ; Lobianco, Christophe ; Salamone, John D. / Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. In: Pharmacology Biochemistry and Behavior. 2013 ; Vol. 105. pp. 105-111.
@article{971d1d9ba4bd4f4c9b126e565d95d268,
title = "Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor",
abstract = "Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. The present experiments were performed to evaluate the ability of safinamide to attenuate parkinsonian motor impairments using the tremulous jaw movement model, an animal model of parkinsonian tremor. In rats, tremulous jaw movements can be induced with dopamine (DA) antagonists, DA depletion, and cholinomimetics, and can be reversed by various antiparkinsonian drugs, including L-DOPA, DA agonists, anticholinergics and adenosine A2A antagonists. In these present experiments, tremulous jaw movements were induced with the anticholinesterase galantamine (3.0 mg/kg IP), the muscarinic agonist pilocarpine (0.5 mg/kg IP), and the dopamine D2 antagonist pimozide (1.0 mg/kg IP). Safinamide significantly reduced the number of tremulous jaw movements induced by galantamine, pilocarpine, and pimozide, with consistent effects across all three drugs at a dose range of 5.0-10.0 mg/kg. The results of this study support the use of safinamide as a treatment for parkinsonian tremor.",
author = "Samantha Podurgiel and Collins-Praino, {Lyndsey E.} and Samantha Yohn and Randall, {Patrick Arthur} and Arthur Roach and Christophe Lobianco and Salamone, {John D.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.pbb.2013.01.015",
language = "English (US)",
volume = "105",
pages = "105--111",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. / Podurgiel, Samantha; Collins-Praino, Lyndsey E.; Yohn, Samantha; Randall, Patrick Arthur; Roach, Arthur; Lobianco, Christophe; Salamone, John D.

In: Pharmacology Biochemistry and Behavior, Vol. 105, 01.04.2013, p. 105-111.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor

AU - Podurgiel, Samantha

AU - Collins-Praino, Lyndsey E.

AU - Yohn, Samantha

AU - Randall, Patrick Arthur

AU - Roach, Arthur

AU - Lobianco, Christophe

AU - Salamone, John D.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. The present experiments were performed to evaluate the ability of safinamide to attenuate parkinsonian motor impairments using the tremulous jaw movement model, an animal model of parkinsonian tremor. In rats, tremulous jaw movements can be induced with dopamine (DA) antagonists, DA depletion, and cholinomimetics, and can be reversed by various antiparkinsonian drugs, including L-DOPA, DA agonists, anticholinergics and adenosine A2A antagonists. In these present experiments, tremulous jaw movements were induced with the anticholinesterase galantamine (3.0 mg/kg IP), the muscarinic agonist pilocarpine (0.5 mg/kg IP), and the dopamine D2 antagonist pimozide (1.0 mg/kg IP). Safinamide significantly reduced the number of tremulous jaw movements induced by galantamine, pilocarpine, and pimozide, with consistent effects across all three drugs at a dose range of 5.0-10.0 mg/kg. The results of this study support the use of safinamide as a treatment for parkinsonian tremor.

AB - Safinamide is an α-aminoamide derivative that is currently in Phase III clinical trial development as an add-on therapy to levodopa or dopamine agonists for patients with Parkinson's disease. Safinamide is a monoamine oxidase B inhibitor with additional non-dopaminergic actions. The present experiments were performed to evaluate the ability of safinamide to attenuate parkinsonian motor impairments using the tremulous jaw movement model, an animal model of parkinsonian tremor. In rats, tremulous jaw movements can be induced with dopamine (DA) antagonists, DA depletion, and cholinomimetics, and can be reversed by various antiparkinsonian drugs, including L-DOPA, DA agonists, anticholinergics and adenosine A2A antagonists. In these present experiments, tremulous jaw movements were induced with the anticholinesterase galantamine (3.0 mg/kg IP), the muscarinic agonist pilocarpine (0.5 mg/kg IP), and the dopamine D2 antagonist pimozide (1.0 mg/kg IP). Safinamide significantly reduced the number of tremulous jaw movements induced by galantamine, pilocarpine, and pimozide, with consistent effects across all three drugs at a dose range of 5.0-10.0 mg/kg. The results of this study support the use of safinamide as a treatment for parkinsonian tremor.

UR - http://www.scopus.com/inward/record.url?scp=84874414183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874414183&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2013.01.015

DO - 10.1016/j.pbb.2013.01.015

M3 - Article

C2 - 23360954

AN - SCOPUS:84874414183

VL - 105

SP - 105

EP - 111

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

ER -